Biochemical Bone Markers, Bone Mineral Content, and Bone Mineral Density in Rats with Experimental Nephrotic Syndrome

References

• Korkor A, Schwartz J, Bergfeld M, Teitelbaum S, Avioli L, Klahr S, Slatopolsky E. Absence of metabolic bone disease in adult patients with the nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1983; 56: 496–500
   Google Scholar
• Lim P, Jacob E, Chio L F, Pwee HS. Serum ionized calcium in nephrotic syndrome. Q J Med (New Ser) 1976; 45: 421–426
   Google Scholar
• Maschio G, D'Angelo A, Bonuccio E, Pagano F, Ossi E, Lupo A, Valvo E, Tessitore N, Messa P. Aspects of calcium metabolism in obstructive nephropathy: a metabolic and bone biopsy investigation. Nephron 1977; 19: 32–43
   Google Scholar
• Malluche H, Goldstein D A, Massry SG. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 1979; 63: 494–500
   PubMed Web of Science ®Google Scholar
• Jones J H, Peters D K, Morgan D B, Coles G A, Mallick NP. Observations on calcium metabolism in the nephrotic syndrome. Q J Med 1967; 36: 301–320
   Google Scholar
• Goldstein D A, Haldimann B, Sherman D, Normam A W, Massry SG. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1981; 52: 116–121
   PubMed Web of Science ®Google Scholar
• Mueller K H, Trias A, Ray RD. Bone density and composition. J Bone Joint Surgery (Am) 1966; 48: 140–148
   PubMed Web of Science ®Google Scholar
• Frost H M. Bone Remodeling and Its Relationship to Metabolic Bone Disease. CC Thomas, Springfield, IL 1973; 92
   Google Scholar
• Wronski T J, Cintron M, Doherty A L, Dann LM. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 1988; 123: 681–686
   PubMed Web of Science ®Google Scholar
• Griffin M G, Kimble R, Hopfer W, Pacifici R. Dual energy x-ray absorptiometry of the rat: accuracy, precision, and measurement of bone loss. J Bone Miner Res 1993; 8: 795–800
   PubMed Web of Science ®Google Scholar
• Frenk S, Antonowicz I, Craig J M, Metcoff J. Experimental nephrotic syndrome induced in rats by amino-nucleoside, renal lesions and body electrolyte composition. Proc Soc Exp Biol Med 1955; 89: 424–427
   PubMed Web of Science ®Google Scholar
• Pyo H J, Summers S N, Nielderberger M, Kim JK, Schrier RW. Arginine vasopressin gene expression in rats with puromycin-induced nephrotic syndrome. Am J Kidney Dis 1995; 25: 58–62
   Google Scholar
• Vernier R L, Papermaster B W, Good RA. Aminonucleoside nephrosis. I. Electron microscopic study of the renal lesion in rats. J Exp Med 1959; 109: 115–126
   PubMed Web of Science ®Google Scholar
• Pedraza-ChaverrÍ J, Cruz C, Ibarra-Rubio ME, Chavez MT, Calleja E, Tapia E, Uribe MC, Romero L, PeÑA JC. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia, and renin-angiotensin-aldosterone system on sodium retention. Rev Invest Clin 1990; 42: 29–38
   PubMedGoogle Scholar
• Committee On Care And Use Of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources, National Research Council, Washington, DC 1985
   Google Scholar
• Lowry O H, Rosenbrough N J, Farr A L, Randall RJ. Protein determination with the Folin phenol reagent. J Biol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Horst R L, Reinhart T A, Hollis BW. Improved methodology for the analysis of plasma vitamin D metabolites. Kidney Int 1990; 38: S28–S35
   Google Scholar
• PØDenphant J, Larsen NE, Christiansen C. An easy and reliable method for the determination of urinary hydroxyproline. Clin Chim Acta 1984; 142: 145–148
   PubMedGoogle Scholar
• Seyedin S M, Kung V T, Daniloff Y N, Hesley R P, Gomez B, Nielsen LA, Roson HN, Zuk RF. Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993; 8: 635–642
   PubMed Web of Science ®Google Scholar
• Wallenstein S, Zucker C L, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980; 47: 1–9
   PubMed Web of Science ®Google Scholar
• Bernard D B. Metabolic abnormalities in nephrotic syndrome: pathophysiology and complications. The Nephrotic Syndrome. Contemporary Issues in Nephrology, BM Brenner, JH Stein. Churchill Livingstone, New York 1982; 9: 85–119.
   Google Scholar
• Pedraza-Chaverri J, Cruz C, ChÁVez MT, Lopez A, Ibarra-Rubio ME, Tapia E, PeÑA JC. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. II. In vitro release of renin, angiotensinogen and aldosterone. Rev Invest Clin 1990; 42: 120–126
   PubMedGoogle Scholar
• Pedraza-ChaverrÍ J, Cruz C, ChÁVez MT, Ibarra-Rubio ME, Tapia E, PeÑA JC. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. III. Effect of captopril, an angiotensin converting enzyme inhibitor, on proteinuria and sodium retention. Rev Invest Clin 1990; 42: 210–216
   PubMedGoogle Scholar
• Lewandowski A E, Liar WSW, Stenson-Fisher CA, Kent J, Jefferson L. Effect of experimentally induced nephrosis on protein synthesis in rat liver. Am J Physiol 1988; 254: C634–C642
   Google Scholar
• Beaman M, Oldfield S, Maclennan ICM, Michael J, Adu D. Hypogammaglobulineamia in nephrotic rats is attributable to hypercatabolism of IgG. Clin Exp Immunol 1988; 74: 425–430
   PubMedGoogle Scholar
• Ricardo S D, Bertram J F, Ryan GB. Reactive oxygen species in puromycin aminonucleoside nephrosis: in vitro studies. Kidney Int 1994; 45: 1057–1069
   PubMed Web of Science ®Google Scholar
• Ibarra-Rubio ME, Cruz C, Tapia E, PeÑA JC, Pedraza-ChaverrÍ J. Serum angiotensin converting enzyme activity and plasma renin activity in experimental models of rats. Clin Exp Pharmacol Physiol 1990; 17: 391–399
   PubMed Web of Science ®Google Scholar
• ArÉValo AE, Ibarra-Rubio ME, Cruz C, PeÑA JC, Pedraza-ChaverrÍ J. Angiotensin I-converting enzyme activity in puromycin aminonucleoside-nephrotic syndrome. Clin Chim Acta 1990; 191: 175–184
   PubMed Web of Science ®Google Scholar
• Liang K H, Oveisi F, Vaziri ND. Gene expression of hepatic cholesterol 7α-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int 1996; 49: 855–860
   Google Scholar
• Levy E, Ziv E, Bar-On H, Shafrir E. Chylomicron synthesis in experimental nephrotic syndrome. Biochim Biophys Acta 1989; 1005: 20–26
   PubMedGoogle Scholar
• Gherardi E, Calandra S. Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside. Biochim Biophys Acta 1981; 710: 188–196
   Google Scholar
• Pedraza-ChaverrÍ J, Cruz C, Ibarra-Rubio ME, HernÁNdez C, Tapia E, PeÑA JC. Urinary excretion of renin and angiotensinogen in nephrotic rats. Nephron 1991; 57: 106–108
   PubMedGoogle Scholar
• Pedraza-ChaverrÍ J, Cruz C, Sandoval AA, Tapia E, PeÑA JC. Effect of captopril on urinary excretion of renin and angiotensinogen in aminonucleoside nephrosis. Renal Failure 1992; 14: 155–159
   PubMed Web of Science ®Google Scholar
• Shafrir E, Levy E, Deckelbaum R. Urinary excretion of apolipoproteins bound to HDL-like particles in rat nephrotic syndrome and their relation to plasma HDL. Nephron 1990; 56: 24–29
   PubMedGoogle Scholar
• Baker B R, Joseph J P, Williams JH. Puromycin synthetic studies. VII. Partial synthesis of amino acid analogs. J Am Chem Soc 1954; 76: 2838
   Google Scholar
• Coers W, Huitema S, Van Der Horst MLC, Weening JJ. Puromycin aminonucleoside and adriamycin disturb cytoskeletal and extracellular matrix protein organization, but not protein synthesis of cultured glomerular epithelial cells. Exp Nephrol 1994; 2: 40–50
   PubMedGoogle Scholar
• Chow S C, Peters I, Orrenius S. Reevaluation of the role of the novo protein synthesis in rat thymocyte apoptosis. Exp Cell Res 1995; 216: 149–159
   PubMedGoogle Scholar
• Ueda N, Baliga R, Shanh SV. Role of “catalytic” iron in an animal model of minimal change nephrotic syndrome. Kidney Int 1996; 49: 370–373
   PubMed Web of Science ®Google Scholar
• Ricardo S D, Bertram J F, Ryan GB. Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol. Exp Nephrol 1995; 3: 270–279
   Google Scholar
• Pedraza-ChaverrÍ J, ArÉValo AE, HernÁNdez-Pando R, Larriva-Sahd J. Effect of dietary antioxidants on puromycin aminonucleoside nephrotic syndrome. Int J Biochem Cell Biol 1995; 27: 683–691
   PubMed Web of Science ®Google Scholar
• Glassock R J, Cohen A H. Primary glomerular diseases. The Kidney, SG Adler, BM Brenner. WB Saunders, Philadelphia 1996; 2: 1392–1497.
   Google Scholar
• Yayama K, Konishi K, Ohta A, Takano M, Ohtani R, Itoh N, Okamoto H. Elevation of plasma angiotensinogen in rats with experimentally induced nephrosis. Nephron 1993; 63: 89–93
   PubMedGoogle Scholar
• Vaziri N D, Gonzales E, Barton C H, Chen H T, Nguyen Q, Arquilla M. Factor XIII and its substrates, fibronectin, fibrinogen, and α2-antiplasmin, in plasma and urine of patients with nephrosis. J Lab Clin Med 1990; 117: 152–156
   Google Scholar
• Vaziri N D, Branson H E, Ness R. Changes of coagulation factors IX, VIII, VII, X, and V in nephrotic syndrome. Am J Med Sci 1980; 280: 167–171
   PubMedGoogle Scholar
• Vaziri N D. Endocrinological consequences of the nephrotic syndrome. Am J Nephrol 1993; 13: 360–364
   PubMed Web of Science ®Google Scholar
• Goldstein D A, Oda Y, Kurokawa K, Massry SG. Blood levels of 25-hydroxyvitamin D in nephrotic syndrome. Ann Intern Med 1977; 87: 664–667
   PubMed Web of Science ®Google Scholar
• Tessitore N, Bonucci E, D'Angelo A, Lund B, Corgnati A, Lund B, Valvo E, Lupo A, Loschiavo C, Fabris A, Machio G. Bone histology and calcium metabolism in patients with nephrotic syndrome and normal or reduced renal function. Nephron 1984; 37: 153–159
   Google Scholar
• Freundlich M, Bourgoignie J J, Zilleruelo G, Abitbol C, Canterbury JM, Strauss J. Calcium and vitamin D metabolism in children with nephrotic syndrome. J Pediatr 1986; 108: 383–387
   PubMed Web of Science ®Google Scholar
• Alon U, Chan JCM. Calcium and vitamin-D metabolism in nephrotic syndrome. Int J Pediatr Nephrol 1983; 4: 115–118
   Google Scholar
• Auwerx J, De Keyser L, Bouillon R, De Moor P. Decreased free 1,25-dihydroxycholecalciferol index in patients with the nephrotic syndrome. Nephron 1986; 42: 231–235
   PubMed Web of Science ®Google Scholar
• Haldimann B, Trechsel U. Vitamin D replacement therapy in patients with the nephrotic syndrome. Miner Elect Metab 1983; 9: 154–156
   Google Scholar
• Lambert P W, De Oreo PB, Fu IY, Kaetzel DM, Von Ahn K, Hollis BW, Ross BA. Urinary and plasma vitamin D3 metabolites in the nephrotic syndrome. Met Bone Dis Rel Res 1982; 4: 7–15
   Google Scholar
• Kano K, Nonoda A, Yoneshima H, Suda T. Serum concentrations of 25-hydroxyvitamin D in patients with various types of renal disease. Clin Nephrol 1980; 14: 274–279
   Google Scholar
• Shimotsuji T, Hiejima T, Seino Y, Yamaoka K, Ishi T, Ishida M, Matsuda S, Ikehara C, Hamabuchi H. A specific competitive protein binding assay for serum 24,25-dihydroxyvitamin D in normal children and patients with nephrotic syndrome. Clin Chim Acta 1980; 106: 145–154
   Google Scholar
• Barragry J M, Carter N D, Beer M, France MW, Auton JA, Boucher BJ, Cohen RD. Vitamin-D metabolism in nephrotic syndrome. Lancet 1977; 2: 629–632
   PubMed Web of Science ®Google Scholar
• Sato K A, Gray R W, Lemann J, Jr. Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Lab Clin Med 1982; 99: 325–330
   PubMedGoogle Scholar
• Khamiseh G, Vaziri N D, Oveisi F, Ahmadnia MR, Ahmadnia L. Vitamin D absorption, plasma concentration and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome. Proc Soc Exp Biol Med 1991; 196: 210–213
   Web of Science ®Google Scholar
• Mizokuchi A, Kubta M, Tomino Y, Koide H. Possible mechanism of impaired calcium and vitamin D metabolism in nephrotic rats. Kidney Int 1992; 42: 335–340
   PubMedGoogle Scholar
• Stickler G B, Hayles A B, Power M H, Ulrich JA. Renal tubular dysfunction complicating the nephrotic syndrome. Pediatrics 1960; 26: 75–85
   Google Scholar
• Stickler G B, Rosevear J W, Ulrich JA. Renal tubular dysfunction complicating the nephrotic syndrome: the disturbance in calcium and phosphorus metabolism. Proc Mayo Clin 1962; 37: 376–388
   Google Scholar
• Schmidt-Gayk H, Grawunder C, Tshope W, Schmitt W, Ritz E, Pietsch V, Andrassy K. 25-Hydroxy-vitamin D in nephrotic syndrome. Lancet 1977; 2: 105–108
   PubMed Web of Science ®Google Scholar
• Emerson K, Jr, Beckman WW. Calcium metabolism in nephrosis. I. A description of an abnormality in calcium metabolism in children with nephrosis. J Clin Invest 1945; 24: 564–572
   Google Scholar
• Lim P, Jacob E, Tock EPC, Pwee HS. Calcium and phosphorus metabolism in nephrotic syndrome. Q J Med (New Ser) 1977; 46: 327–338
   Google Scholar
• Chesney R W, Mazess R B, Rose P, Jax DK. Effect of prednisone on growth and bone mineral content in childhood glomerular disease. Am J Dis Child 1978; 132: 768–772
   PubMedGoogle Scholar
• Price P A, Nashimoto SK. Radioimmunoassay for the vitamin K dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci USA 1980; 77: 2234–2238
   PubMed Web of Science ®Google Scholar
• Slovick D M, Gundberg C M, Neer R M, Lian BJ. Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting. J Clin Endocrinol Metab 1984; 59: 228–230
   Google Scholar
• Azria M. Value of biomarkers in detecting alterations in bone metabolism. Calcif Tissue Int 1989; 45: 7–11
   PubMed Web of Science ®Google Scholar
• Malluche H H, Fanti P, Faugere M C, Price PA. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 1984; 26: 869–874
   PubMedGoogle Scholar
• Deftos L J, Parthemore J G, Price PA. Changes in plasma bone Gla-protein during treatment of bone disease. Calcif Tissue Int 1982; 34: 121–124
   PubMed Web of Science ®Google Scholar
• Rico H, Espinos D, Del Rio A, Hernandez ER. Treatment of postmenopausal and calcium—long-term results. Proc 2nd Int Conf on Osteoporosis, Athens 1985; 376–380
   Google Scholar
• Delmas P D, Wilson D M, Mann K G, Riggs BL. Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 1983; 57: 1028–1030
   PubMed Web of Science ®Google Scholar
• Guillemant J, Guillemant S. Plasma osteocalcin in primary and secondary hyperparathyroidism with regard to daily fluctuations. Horm Metab Res 1989; 21: 220–221
   Google Scholar
• Gundberg C M, Grant F D, Conlin P R, Chen C J, Brown E M, Johnson P J, Leboff MS. Acute changes in serum osteocalcin during induced hypocalcemia in humans. J Clin Endocrinol Metab 1991; 72: 438–443
   PubMed Web of Science ®Google Scholar
• Deftos L J. Bone protein and peptide assay in the diagnosis and management of skeletal disease. Clin Chem 1991; 37: 1143–1148
   PubMed Web of Science ®Google Scholar
• Pedraza-ChaverrÍ J, Cruz C, Tapia E, PeÑA JC. Activity of serum enzymes in puromycin aminonucleoside-induced nephrotic syndrome. Renal Failure 1992; 14: 523–531
   PubMed Web of Science ®Google Scholar
• Price R G, Ellis BG. Urinary enzyme excretion in aminonucleoside nephrosis in rats. Chem-Biol Interact 1976; 13: 353–358
   PubMedGoogle Scholar
• Mani U V, Mani I. Altered urinary excretion of hydroxyproline in nephrotic syndrome patients. J Clin Biochem Nutr 1989; 6: 155–158
   Google Scholar
• Krane S, MuÑOz AJ, Harris ED, Jr. Urinary polypeptides related to collagen synthesis. J Clin Invest 1970; 49: 716–729
   PubMed Web of Science ®Google Scholar
• Delmas P D. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocr Metab Clin North Am 1990; 19: 1–17
   PubMed Web of Science ®Google Scholar